[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hypopharynx-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hypopharynx-cancer":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,57,89,123,155,183],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":56},"100592718","phase-2-methotrexate-erlotinib-and-celecoxib-for-the-treatment-of-recurrentmetastatic-head-and-neck-cancer-in-a-rural-midwest-united-states-population-100592718",false,"NCT06997068","Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent\u002FMetastatic Head and Neck Cancer in a Rural Midwest United States Population","MC240701 Decentralized Pilot Study of Triple Oral Metronomic Chemotherapy for Patients With Recurrent\u002FMetastatic Head and Neck Cancer in a Rural Midwest United States Population","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Histologically confirmed diagnosis of relapsed\u002Fmetastatic head and neck cancer, including oral cavity, oropharynx \\[human papillomavirus (HPV) positive and negative), hypopharynx, and larynx cancer\n* Measurable or non-measurable disease is allowed\n\n  * Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria\n  * Non-measurable disease\n\n    * NOTE: Other nonmeasurable lesions include clinically evident lesions not well visualized on imaging \\[e.g., oral cavity mass readily seen on physical exam but obscured on computed tomography (CT)\\], dermal metastases, and bone metastases\n* Prior treatment:\n\n  * One of the following must be true:\n\n    * Received standard 1st-line immunotherapy or chemo-immunotherapy OR\n    * Unable to receive or refuse 1st-line therapy\n* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0, 1 or 2\n* Hemoglobin ≥ 9.0 g\u002FdL (obtained 15 days prior to registration)\n* Absolute neutrophil count (ANC) ≥ 1500\u002Fmm\\^3 (obtained 15 days prior to registration)\n* Platelet count ≥ 100,000\u002Fmm\\^3 (obtained 15 days prior to registration)\n* Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (obtained 15 days prior to registration)\n* Alanine aminotransferase (ALT) and aspartate transaminase (AST) ≤ 3 x ULN (≤ 5 x ULN for patients with liver involvement) (obtained 15 days prior to registration)\n* Prothrombin time (PT)\u002Finternational normalized ratio (INR)\u002Factivated partial thromboplastin time (aPTT) ≤ 1.5 x ULN OR if patient is receiving anticoagulant therapy and INR or aPTT is within target range of therapy (obtained 15 days prior to registration)\n* Calculated creatinine clearance ≥ 45 ml\u002Fmin per Chronic-Kidney Disease-Epidemiology (CKD-EPI) Creatinine Equation (obtained 15 days prior to registration)\n* Estimated creatinine clearance (Clcr) by the CKD-EPI Creatinine Equation (per National Kidney Foundation) (obtained 15 days prior to registration)\n* Negative pregnancy test done ≤ 8 days prior to registration, for persons of childbearing potential only\n* Provide written informed consent\n* Ability to complete questionnaire(s) by themselves or with assistance\n* Ability to swallow pills\n* Willing and able to adhere with the protocol schedule for the duration of the study including undergoing treatment, attending scheduled visits, and examinations\n\nExclusion Criteria:\n\n* Any of the following because this study involves an investigational agent, the genotoxic, mutagenic, and teratogenic effects of which on the developing fetus and newborn are unknown\n\n  * Pregnant persons\n  * Nursing persons\n  * Persons of childbearing potential and persons able to father a child who are unwilling to employ adequate contraception\n* Uncontrolled intercurrent illness including, but not limited to:\n\n  * Myocardial infarction ≤ 6 months prior to registration\n  * New York Heart Association (NYHA) class III or IV heart failure\n  * Corrected QT interval (QTc) prolongation more than 440 ms in males and 460 ms in females\n  * Uncontrolled dysrhythmias or poorly controlled angina\n  * History of serious ventricular arrhythmia \\[ventricular tachycardia (VT) or ventricular flutter (VF)\\] and\u002For factors that predispose to arrhythmia (e.g., heart failure, hypokalemia, family history of long QT syndrome)\n  * Ongoing or active infection requiring systemic treatment\n  * Active gastrointestinal bleeding\n  * Psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n* Immunocompromised patients and patients known to be HIV positive and currently receiving antiretroviral therapy\n\n  * NOTE: Patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial\n* Known hepatitis\n\n  * Exception: For patients with evidence of chronic hepatitis B virus infection the hepatitis B (HepB) viral load must be undetectable on suppressive therapy, if indicated, to be eligible\n  * Exception: Patients with a history of hepatitis C virus infection must have been treated and cured. Patients with hepatitis C virus (HCV) infection who are currently on treatment are eligible if they have an undetectable HCV viral load\n* Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm\n* Other active malignancy requiring therapy such as radiation, chemotherapy, or immunotherapy. Patients on hormonal therapy for treated breast or prostate cancer are permitted if they meet other eligibility criteria\n\n  * NOTE: Patients with secondary malignancy with life expectancy ≥ 2 years are eligible\n* Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens","ALL","18 Years",{"count":19,"type":20},25,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This phase II trial gathers information on the feasibility, safety, and effect of giving methotrexate, erlotinib, and celecoxib in treating head and neck cancer that has come back after a period of improvement (recurrent) or that has spread from where it first started (primary site) to other places in the body (metastatic) among rural Midwest patients. Methotrexate is in a class of medications called antimetabolites. It is also a type of antifolate. Methotrexate stops cells from using folic acid to make deoxyribonucleic acid and may kill tumor cells. Erlotinib is in a class of medications called kinase inhibitors. It works by blocking the action of a protein called EGFR that signals tumor cells to multiply. This helps slow or stop the spread of tumor cells. Celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving the combination of methotrexate, erlotinib, and celecoxib may be feasible, safe, and effective in treating rural Midwest patients with recurrent\u002Fmetastatic head and neck cancer.",[26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43],"Metastatic Oral Cavity Carcinoma","Recurrent Oral Cavity Carcinoma","Stage IVC Lip and Oral Cavity Cancer AJCC v8","Head and Neck Cancer","Hypopharynx Cancer","Oropharynx Cancer","Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","Metastatic Hypopharyngeal Carcinoma","Metastatic Laryngeal Carcinoma","Metastatic Malignant Head and Neck Neoplasm","Metastatic Oropharyngeal Carcinoma","Recurrent Hypopharyngeal Carcinoma","Recurrent Laryngeal Carcinoma","Recurrent Malignant Head and Neck Neoplasm","Recurrent Oropharyngeal Carcinoma","Stage IVC Hypopharyngeal Carcinoma AJCC v8","Stage IVC Laryngeal Cancer AJCC v8","Stage IVC Oropharyngeal (p16-Negative) Carcinoma AJCC v8","RECRUITING","2026-05-07",{"date":47,"type":48},"2026-05-11","ACTUAL",{"date":50,"type":48},"2025-07-09",{"date":52,"type":20},"2028-06-30",{"name":54,"class":55},"Mayo Clinic","OTHER",1,{"id":58,"slug":59,"hasResults":11,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":65,"targetDuration":4,"studyType":21,"phases":67,"briefSummary":69,"conditions":70,"keywords":73,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":88},"100570373","phase-3-lymphocyte-sparing-and-radio-immunotherapy-in-head-and-neck-carcinoma-100570373","NCT06706401","Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck Carcinoma","A Multicenter, Randomised 2*2 Factorial Design Comparing Standard to Reduced-target Volume Radiotherapy With or Without All-trans Retinoic Acid (ATRA) in Patients With Lateralised Oropharyngeal, Laryngeal and Hypopharyngeal Squamous Cell Carcinoma.","LYSARI","Inclusion criteria :\n\nI1. Male or female patients aged ≥ 18 years old at time of inform consent signature.\n\nI2. Patients with primary head and neck tumour up to, but not crossing the midline, previously untreated with histologically-confirmed squamous cell carcinoma of:\n\n* the oropharynx p16-, larynx or hypopharynx : T1\u002FN2a-N2b, T2\u002FN0-N2b, T3\u002FN0-N2b (UICC 8th Ed.), or\n* the oropharynx p16+ : T1\u002FN1 (multiple nodes), T2-T3\u002FN0-N1 (UICC 8th Ed.).\n\nI3. Patients with lymph node staging assessed by an FDG-PET\u002FCT with no contralateral nodal uptake.\n\nI4. Patients amenable to treatment with RT or concomitant chemo-radiotherapy as decided by the treating physician as a function of tumor stage, tumor location, performance of the patients.\n\nI5. Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1.\n\nI6. Adequate hematologic and end-organ function, defined by the following laboratory test results obtained within 7 days prior to randomisation :\n\nHematological (without transfusion within 2 weeks) :\n\n* Neutrophils count \\> 1.5 × 109 \u002FL\n* Platelets count \\> 75 × 109 \u002FL\n* WBC≥ 3.0 × 109 \u002FL\n\nHepatic function :\n\n* Total Bilirubin \\\u003C 1.5 × ULN (except for Gilbert's syndrome which will allow bilirubin ≤ 3 ULN).\n* Alanine aminotransferase (ALT) ≤ 2.5 × ULN.\n* Aspartate aminotransferase (AST) ≤ 2.5 × ULN.\n* Albumin \\>3.0g\u002FdL\n\nRenal function :\n\n* Serum creatinine \\\u003C 1.5 ×ULN.\n\nI7. QTcF ≤450ms for men and 470ms for women, from 3 electrocardiograms on screening ECG, within 7 days prior randomisation.\n\nI8. Women patients of child-bearing potential are eligible, provided they have a negative serum or urine pregnancy test within 7 days prior randomisation, and agrees to use adequate contraception for up to 1 month after the end of study treatments.\n\nI9. Fertile men must agree to use an effective method of contraception during the study and for up to 1 month after the end of study treatments.\n\nI10. Patient should understand, sign, and date the written voluntary informed consent form prior to any protocol-specific procedures performed and should be able and willing to comply with study visits and procedures as per protocol.\n\nI11. Patients must be covered by a medical insurance in country where applicable.\n\nExclusion criteria :\n\nE1. Patient with primary tumor crossing the midline or patients with bilateral primary tumors.\n\nE2. Patients with T1-N0 (p16-), T1-N1 (p16-), T1-N0 (p16+), T4 (p16- and p16+), bilateral lymph nodes or nodal disease more than 6 cm (p16- and p16+).\n\nE3. Patients with unknown primary tumor size as per TNM i.e. T0-N1 to T0-N3, p16- or p16+.\n\nE4. Patients with contralateral FDG-PET\u002FCT nodal uptake.\n\nE5. Patient with any previous anti-cancer therapy for HNSCC (all prior treatment are forbidden: chemotherapy, radiotherapy, targeted therapy, immunotherapy or any other therapy approved or experimental).\n\nE6. Patient with malignancies other than HNSCC within 3 years prior to randomisation with the exception of adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localised prostate cancer treated surgically with curative intent.\n\nE7. Patient with ongoing or anticipation of need for systemic immunosuppressive medication (including, but not limited to, glucocorticoids, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-TNF-alpha agents); with the exceptions of intranasal, inhaled or topical corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg\u002Fday of prednisone, or an equivalent corticosteroid.\n\nE8. Patient with ongoing or anticipation of need for systemic immunostimulatory agents (including, but not limited to, interferons and IL-2).\n\nE9. Patient with concurrent treatment with any other anti-cancer treatment, approved or investigational agent or participation in another clinical trial with therapeutic intent.\n\nE10. Patient with infectious diseases :\n\n* Severe infection within 4 weeks prior to randomisation, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia,\n* Active hepatitis B (chronic or acute; defined as having a positive hepatitis B surface antigen \\[HBsAg\\] test at screening),\n* Active hepatitis C. Patients positive for hepatitis C virus (HCV) antibody are eligible only if PCR is negative for HCV RNA at screening,\n* HIV infection,\n* Active tuberculosis.\n\nE11.Patient with any psychological, cognitive, familial, sociological or geographical condition potentially hampering compliance with the study protocol, completion of patient reported measures and follow-up schedule; those conditions should be discussed with the patient before registration in the trial.\n\nE12. Patient with known hypersensitivity to tretinoin, other retinoids, soya, peanut or to any of the excipients of vesanoid.\n\nE13. Patient with known malabsorption syndrome and\u002For unable to swallow oral medication.\n\nE14.Patient with ongoing or expected need for concomitant treatment with vitamin A, tetracyclines, other retinoids, anti-fibrinolytic agent, and strong inducers or inhibitors of CYP3A4.\n\nE15.Pregnant or lactating woman.",{"count":66,"type":20},460,[68],"PHASE3","The aim of this study is to investigate the effect of ATRA (Vesanoid) and the effect of tailored radiotherapy in patients with squamous cell carcinoma of the oropharynx, larynx or hypopharynx.",[31,71,30,72],"Larynx Cancer","Primary Head and Neck Tumor",[74,75,76,77,78],"Localised squamous cell carcinoma of head and neck","Previously untreated","Standard radiotherapy","Tailored radiotherapy","Vesanoid","2026-04-21",{"date":81,"type":48},"2026-04-24",{"date":83,"type":48},"2025-02-20",{"date":85,"type":20},"2029-01",{"name":87,"class":55},"Centre Leon Berard",8,{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":4,"eligibilityCriteria":95,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":96,"targetDuration":4,"studyType":21,"phases":98,"briefSummary":99,"conditions":100,"keywords":110,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":122},"100597801","phase-2-a-study-of-sacituzumab-govitecan-in-combination-with-cetuximab-in-people-with-head-and-neck-squamous-cell-cancer-hnscc-100597801","NCT07063212","A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)","A Phase II Study of Sacituzumab Govitecan in Combination With Cetuximab in Patients With Recurrent Metastatic HNSCC That Has Progressed After First-Line Therapy","Inclusion Criteria:\n\n* Pathologically (histologically or cytologically) proven diagnosis of squamous cell carcinoma of the head and neck arising from the sinuses, nasal cavity, oral cavity, oropharynx, hypopharynx, and larynx. Other sites not listed will be subject to PI discretion.\n\n  * Advanced disease (Stage IV or M1 disease) not amenable to curative local therapy with surgery and\u002For radiation based approaches\n  * Progression on first line anti-PD(L)1 therapy with or without chemotherapy or as part of a combination in a clinical trial\n  * HPV status for oropharynx primary must be previously confirmed or can be performed on available archival or fresh biopsy via p16 immunohistochemistry or HPV specific testing via PCR or RNA ISH. Patients are able to enroll and initiate treatment so long as this is in progress. Exceptions may be made after discussion and review with P.I.\n  * Have measurable disease per RECIST v1.1 criteria. Tumor lesions situated in previously radiated area may be utilized if they are measurable and progression has been demonstrated in these lesions.\n* Male or female patients 18 years of age or older on the day of consent.\n* ECOG Performance Status of 0 to 1.\n* Adequate hematologic function within 30 days prior to registration, defined as follows:\n\n  * Absolute neutrophil count (ANC) ≥ 1,500 cells\u002Fmm3\n  * Platelets ≥ 100,000 cells\u002Fmm3\n  * Hemoglobin ≥ 9.0 g\u002Fdl; Note: The use of transfusion or other intervention to achieve Hgb ≥ 9.0 g\u002Fdl is acceptable\n* Adequate renal function within 30 days prior to registration, defined as follows:\n\n  o Serum creatinine \\\u003C 2.0 x upper limit of normal (ULN) or creatinine clearance (CCr)\n\n  ≥ 30 ml\u002Fmin determined by 24-hour collection or estimated by Cockcroft-Gault formula: CCr male = \\[(140 - age) x (wt in kg)\\] \\[(Serum Cr mg\u002Fdl) x (72)\\] CCr female = 0.85 x (CrCl male)\n* Adequate hepatic function within 30 days prior to registration, defined as follows:\n\n  * Total bilirubin ≤ 1.5 × ULN (except for unconjugated hyperbilirubinemia or Gilbert's syndrome). Direct bilirubin ≤ ULN for participants with total bilirubin levels \\> 1.5 × ULN.\n  * AST and ALT \\\u003C 2.5 x the upper limit of normal\n  * Albumin ≥ 3 g\u002FdL\n* International Normalized Ratio (INR) or Prothrombin Time (PT) ≤ 1.5 × ULN unless participant is receiving anticoagulant therapy as long as PT or partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulants.\n* Activated Partial Thromboplastin Time (aPTT) or Partial Thromboplastin Time (PTT) ≤ 1.5 × ULN unless participant is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants.\n* Female patients are eligible to participate if they are not pregnant, not breastfeeding and at least one of the following conditions applies:\n\n  * Not a woman of childbearing potential\n  * A woman of childbearing potential who agrees to use highly effective contraception from signing of the ICF through six months after the last study treatment administration.\n\nNotes:\n\ni. Female of childbearing potential are those who have not been surgically sterilized or have not been free from menses for \\>1 year. ii. Highly effective contraception methods include:\n\n* Total abstinence\n* Male or female sterilization\n* Combination of any 2 of the following categories (Categories 1+2, 1+3, or 2+3):\n\n  * Category 1: Use of oral, injected, or implanted hormonal methods of contraception.\n  * Category 2: Placement of an intrauterine device or intrauterine system.\n  * Category 3: Category 3: Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical\u002Fvault caps) with spermicidal foam\u002Fgel\u002Ffilm\u002Fcream\u002Fvaginal suppository.\n  * A female participant who is of childbearing potential must have a negative serum β-human chorionic gonadotrophin (β-hCG) pregnancy test within 72 hours prior to the first administration of study treatment or be surgically\u002Fbiologically sterile (hysterectomy or bilateral oophorectomy) or postmenopausal. Note: Postmenopausal females are defined as those who are:\n* Age \\> 50 years with amenorrhea for ≥ 12 months.\n* Age ≤ 50 years with six months of spontaneous amenorrhea and follicle stimulating hormone level within postmenopausal range (\\> 40 mIU\u002FmL).\n\n  * Male patients must agree to use contraception and refrain from sperm and egg donation from the time period between signing of the ICF and through five months after the last dose of study drug\n  * The subject must provide voluntary study-specific informed consent prior to study entry.\n\nExclusion Criteria:\n\n* Patients must not have received more than 2 prior line of systemic treatment (i.e. in the second or third line of treatment) in the recurrent\u002Fmetastatic setting.\n\n  o Ambiguity regarding lines of treatment a patient has received will be subject to PI review and approval.\n* Patients with previous severe infusion or allergic reactions to EGFR antibody based therapy that is deemed unsafe for re-challenge based on assessment by PI and\u002For consultation with allergy\u002Fimmunology.\n* Patients who have previously received topoisomerase I inhibitors for HNSCC\n* Patients who have a confirmed or suspected diagnosis (subject to P.I. discretion) of Gilbert's Syndrome\n* Have had a prior anti-cancer biologic agent, chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1.\n* Have not recovered (ie, ≤ Grade 1) from AEs due to a previously administered agent.\n\n  * Note: Subjects with ≤ Grade 2 neuropathy or ≤ Grade 2 alopecia are exceptions to this criterion and may qualify for the study.\n  * Note: If subjects underwent major surgery, they must have recovered adequately from the toxicity and\u002For complications from the intervention prior to starting study drug.\n  * Note: Subjects with Grade ≤ 2 immune-mediated toxicities (except colitis which must be recovered, \\\u003C Grade 1) related to immunotherapy and\u002For radiation treatment that are long lasting, but stable on treatment and not requiring agents that are excluded by this protocol may qualify for the study.\n* Patients with simultaneous primary cancers aside from HNSCC will be excluded unless otherwise approved by PI.\n* Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for 3 years or if cure rate for the malignancy treated at 5 years is estimated to be 90% or greater, unless otherwise approved by PI\n* Severe, active co-morbidity defined as the following:\n\n  * Unstable angina and\u002For congestive heart failure requiring hospitalization within the last 6 months\n  * Transmural myocardial infarction within the last 6 months\n  * Acute infection requiring intravenous therapy at the time of registration\n  * Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days of registration\n  * Hepatic Insufficiency resulting in clinical jaundice and\u002For coagulation defect\n* Have known active central nervous system (CNS) metastases and\u002For carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they have stable CNS disease for at least 4 weeks prior to the first dose of study drug and all neurologic symptoms have returned to baseline, no evidence of new or enlarging brain metastases and are taking ≤ 20 mg\u002Fday of prednisone or its equivalent. All subjects with carcinomatous meningitis are excluded regardless of clinical stability.\n* Have active chronic inflammatory bowel disease (ulcerative colitis, Crohn's disease), immune-mediated colitis, or gastrointestinal (GI) perforation within 6 months of C1D1.\n* Known acquired immunodeficiency syndrome due to untreated\u002Fpoorly controlled human immunodeficiency virus. Other diagnosed immunodeficiency syndromes or disorders will require the review and approval of the site PI.\n* Positive test for hepatitis B surface antigen (HBsAG) or hepatitis C virus antibody (anti-HCV), indicating acute or chronic infection. Patients who test positive for anti-HCV but negative for HCV ribonucleic acid (RNA) are permitted to enroll.\n* Herbal remedies known to potentially interfere with major organ function within 28 days prior to the first dose of study treatment, unless agreed otherwise between the PI and treating investigator.\n* Female patients who are pregnant, breastfeeding, or plan on becoming pregnant during the study.",{"count":97,"type":20},40,[23],"The purpose of this study to find out whether sacituzumab govitecan in combination with cetuximab is an effective and safe treatment approach for people with recurrent and\u002For metastatic head and neck squamous cell cancer (HNSCC).",[101,102,103,104,31,30,71,105,106,107,108,109],"Squamous Cell Carcinoma of Head and Neck","Sinus Cancer","Nasal Cavity Cancer","Oral Cavity Cancer","Oral Squamous Cell Carcinoma","Oropharynx Squamous Cell Carcinoma","Hypopharynx Squamous Cell Carcinoma","Larynx Squamous Cell Carcinoma","HPV Positive Oropharyngeal Squamous Cell Carcinoma",[101,102,103,104,31,30,71,105,106,107,108,109,111,112,113],"Sacituzumab Govitecan","25-094","Memorial Sloan Kettering Cancer Center","2026-02-17",{"date":116,"type":48},"2026-02-19",{"date":118,"type":48},"2025-07-02",{"date":120,"type":20},"2028-01-02",{"name":113,"class":55},7,{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":127,"acronym":128,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":16,"minAge":130,"maxAge":4,"enrollmentInfo":131,"targetDuration":4,"studyType":133,"phases":4,"briefSummary":134,"conditions":135,"keywords":137,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":154},"100465202","special-care-patterns-for-elderly-hnscc-patients-undergoing-radiotherapy-100465202","NCT05337631","Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy","SENIOR","Inclusion Criteria:\n\n* definitive (chemo-)radiotherapy of locoregionally advanced (cT3-4 and\u002For cN+) head-and-neck squamous cell carcinomas (HNSCC) of the oral cavity, oropharynx, hypopharynx or larynx\n* primary treatment since 2005\n* age ≥65 years at the time of (chemo-)radiotherapy\n\nExclusion Criteria:\n\n* adjuvant (chemo-)radiotherapy\n* history of previous head-and-neck cancers or radiotherapy in the head-and-neck region\n* distant metastases at (chemo-)radiotherapy initiation (cM1)\n* HNSCCs of the nasopharynx, salivary glands, skin or with unknown primary","65 Years",{"count":132,"type":20},1500,"OBSERVATIONAL","The number of elderly head-and-neck squamous cell carcinoma (HNSCC) patients is increasing; however, the evidence regarding the ideal treatment for this often vulnerable and frail patient cohort is limited. Although the benefit of concomitant chemotherapy has been reported to decrease in elderly HNSCC patients based on the MACH-NC meta-analysis, it remains unknown whether state-of-the art radiotherapy techniques such as intensity-modulated radiotherapy (IMRT), modern supportive treatments and alternative chemotherapy fractionation (e.g., cisplatin weekly) may have altered this observation. The objective of this retrospective multinational multicenter study is to determine the oncological outcomes of elderly patients (≥65 years) with locally advanced HNSCCs undergoing definitive (chemo-)radiation and to investigate the influence of concomitant chemotherapy on overall survival and progression-free survival after adjusting for potential confounder variables such as age, performance status and comorbidity burden.",[136,104,31,30,71],"HNSCC",[138,139,140,141,142,143,144],"Elderly","Radiotherapy","Chemotherapy","Chemoradiotherapy","Cisplatin","Cetuximab","Real-world data","2025-03-24",{"date":147,"type":48},"2025-03-25",{"date":149,"type":48},"2021-06-01",{"date":151,"type":20},"2026-12-31",{"name":153,"class":55},"University Hospital Freiburg",18,{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":159,"acronym":4,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":161,"enrollmentInfo":162,"targetDuration":4,"studyType":21,"phases":164,"briefSummary":165,"conditions":166,"keywords":168,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":56},"100563051","phase-2-sbrt-followed-by-chemoimmunotherapy-of-toripalimab-plus-docetaxel-and-cisplatin-for-larynx-preservation-in-patients-with-locally-regionally-advanced-squamous-cell-carcinoma-of-the-larynx-and-hypopharynx-100563051","NCT06611137","SBRT Followed by Chemoimmunotherapy of Toripalimab Plus Docetaxel and Cisplatin for Larynx Preservation in Patients with Locally Regionally Advanced Squamous Cell Carcinoma of the Larynx and Hypopharynx","Inclusion Criteria:\n\n* Laryngeal (T3-4N0-3M0 ) and hypopharyngeal ( T2-4N0-3M0) cancers staged by AJCC8th\n* age 18-70\n* PS score 0-1\n* normal functions to tolerate chemotherapy, immunotherapy and radiotherapy\n\nExclusion Criteria:\n\n* Patients with a combination of other malignant tumours\n* Individuals with contraindications to immunotherapy","70 Years",{"count":163,"type":20},35,[23],"This trial aims to evaluate the safety and efficiency of SBRT followed by Chemoimmunotherapy of Toripalimab Plus Docetaxel and Cisplatin for Patients with Locally Regionally Advanced Squamous Cell Carcinoma of the Larynx and Hypopharynx",[167,30],"Laryngeal Cancer",[169,170,171,172,173],"SBRT","immunotherapy","larynx preservation","laryngeal cancer","hypopharynx cancer","2024-09-25",{"date":176,"type":48},"2024-09-26",{"date":178,"type":48},"2024-09-11",{"date":180,"type":20},"2027-09-11",{"name":182,"class":55},"Sun Yat-sen University",{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":4,"eligibilityCriteria":189,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":161,"enrollmentInfo":190,"targetDuration":4,"studyType":21,"phases":192,"briefSummary":193,"conditions":194,"keywords":4,"overallStatus":196,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":56},"100558661","phase-2-tislelizumab-and-induction-chemotherapy-for-larynx-preservation-in-resectable-advanced-laryngealhypopharyngeal-cancer-100558661","NCT06554028","Tislelizumab and Induction Chemotherapy for Larynx Preservation in Resectable Advanced Laryngeal\u002FHypopharyngeal Cancer","Tislelizumab and Induction Chemotherapy Followed by Radiotherapy or Adaptive Surgery for Larynx Preservation in Resectable Locally Advanced Laryngeal or Hypopharyngeal Cancer: A Single-Arm Phase II Clinical Trial","Inclusion Criteria:\n\n1. Pathologically confirmed, resectable locally advanced laryngeal\u002Fhypopharyngeal squamous cell carcinoma (T2-4a, N0-resectable N3, M0);\n2. Age between 18-70 years;\n3. Had at least one measurable lesion according to RECIST 1.1 criteria;\n4. Anticipated overall survival more than 3 months;\n5. Satisfactory performance status: ECOG (Eastern Cooperative Oncology Group) scale 0-1;\n6. Normal organ function;\n7. Male and no pregnant female, able to adapt birth control methods during treatment;\n8. Signed inform consent;\n\nExclusion Criteria:\n\n1. Hypersensitivity to tislelizumab, Paclitaxel or Cisplatin.\n2. Received anti-tumor treatment in the past 6 months, including radiotherapy and chemotherapy, surgery, immunotherapy.\n3. Suffered from malignant tumors, except cervical carcinoma in situ, papillary thyroid carcinoma, or skin cancer (non- melanoma) within five years.\n4. There is distant metastasis.\n5. Active autoimmune diseases, history of autoimmune diseases (such as interstitial pneumonia, colitis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism, including but not limited to these diseases or syndromes); but excludes autoimmune-mediated hypothyroidism on stable doses of thyroid replacement hormone; type 1 diabetes on stable doses of insulin; vitiligo or resolved childhood asthma\u002Fallergies, Patients who do not require any intervention after adulthood.\n6. Known history of primary immunodeficiency (including positive HIV test, or suffering from other acquired or congenital immunodeficiency diseases, or history of organ transplantation and allogeneic bone marrow transplantation);\n7. Severe infection occurred within 4 weeks before the first use of the study drug, such as severe pneumonia requiring hospitalization, bacteremia, infection complications, etc.\n8. The subject has severe liver and kidney dysfunction, HIV infection, HCV infection, uncontrolled clinical symptoms or diseases of the heart, such as: heart failure above NYHA grade II or echocardiography，showing left ventricular ejection fraction (LVEF) \\\u003C 50%; unstable angina; myocardial infarction within 1 year; patients with clinically significant supraventricular or ventricular arrhythmias requiring clinical，intervention (including QTc interval ≥ 470 ms); uncontrolled diabetes, uncontrolled Patients with high blood pressure, hypertensive crisis or hypertensive encephalopathy or other diseases considered by the researchers to be ineligible.\n9. Patients with untreated chronic hepatitis B or chronic hepatitis B virus (HBV) DNA exceeding 500 IU\u002Fml, or patients with active hepatitis C virus (HCV) should be excluded; inactive hepatitis B surface Antigen carriers, treated and stable hepatitis B patients (HBV DNA\\\u003C500IU\u002Fml), and cured hepatitis C patients can be enrolled.\n10. Have a history of interstitial lung disease (excluding radiation pneumonitis that has not been treated with hormones) and non-infectious pneumonia.\n11. Active tuberculosis infection was found through medical history or CT examination, or patients with a history of active tuberculosis infection within 1 year before enrollment, or patients with a history of active tuberculosis infection more than 1 year ago but without formal treatment.\n12. Patients who have received any of the following treatments (1) Subjects who need to be given corticosteroids (\\> 10 mg prednisone equivalent dose per day) or other immunosuppressants for systemic treatment within 2 weeks before the first use of the study drug, except for local inflammation and prevention of allergies and nausea, Cases of use of corticosteroids for vomiting. In the absence of active autoimmune disease, corticosteroid replacement with inhaled or topical steroids and curative doses of prednisone \\>10 mg\u002Fday is permitted; (2) Have been vaccinated against tumors; those who have been vaccinated or have been vaccinated with live vaccines within 4 weeks before the first administration of the study drug; (3) Received major surgery or severe trauma within 4 weeks before the first use of the study drug; (4) Enrolled in another clinical study at the same time.\n13. Pregnant and lactating women. Women of childbearing age must take a pregnancy test within 7 days before enrollment Negative.\n14. Substance abuse, clinical or psychological or social factors that hinder informed consent or research conduct influences.\n15. Any uncertain factors affecting the safety or compliance of the subjects.",{"count":191,"type":20},46,[23],"This study is a prospective, single-arm, single-center, phase II study. The goal of this clinical trial is to explore the therapeutic value of the treatment model of \"tislelizumab combined with chemotherapy followed by radiotherapy\u002Fadaptive surgery\" on larynx Preservation of locally advanced hypopharyngeal cancer and laryngeal cancer.",[167,30,195],"Laryngeal Neoplasms","NOT_YET_RECRUITING","2024-08-12",{"date":199,"type":48},"2024-08-14",{"date":201,"type":20},"2024-08",{"date":203,"type":20},"2027-12",{"name":205,"class":206},"Henan Cancer Hospital","OTHER_GOV"]